RESUMO
Since the beginning of RHD genotyping in maternal plasma, no Rh D positive baby was diagnosed RHD negative in our institution. Genotyping from circulating DNA in maternal plasma is as efficient as genotyping on amniocyts but without the associated risks. We propose a prophylactic injection based on fetal genotyping RHD in maternal blood with 300 microg anti-D immunoglobulin at 28 weeks of amenhorrea in all of Rh D negative pregnant women whitch fetuses positive RHD.
Assuntos
Sangue Fetal/química , Gravidez/sangue , Cuidado Pré-Natal , Sistema do Grupo Sanguíneo Rh-Hr/genética , DNA/sangue , Éxons/genética , Feminino , Seguimentos , Genótipo , Humanos , Fatores Imunológicos/uso terapêutico , Recém-Nascido , Masculino , Valor Preditivo dos Testes , Isoimunização Rh/prevenção & controle , Sistema do Grupo Sanguíneo Rh-Hr/análise , Imunoglobulina rho(D)/uso terapêutico , Sensibilidade e EspecificidadeRESUMO
Antinuclear antibody (ANA) immunofluorescence tests, using HEp-2 cells, were performed on 100 children without a history of connective tissue disease. Eighteen (18%) were positive at titres greater than or equal to 1:40, nine (9%) being greater than 1:160. Interlaboratory variability was demonstrated with some specimens. No association with possible intercurrent infection was found to account for positive results. Of 44 children with proven infections five (11%) were positive. Antinuclear antibody may be found in some normal children when using the sensitive HEp-2 cell substrate, and in the absence of clinical features should not necessarily suggest the presence of a connective tissue disease.
